Molecular basis for redox control by the human cystine/glutamate antiporter system xc
Methylene Blue can also interact with other drugs: for example, it may increase the effects of stimulants (like amphetamines) or certain blood pressure medications, and it might reduce the effectiveness of drugs that rely on nitric oxide (like nitroglycerin)
A cautious, informed approach guided by a healthcare professional remains the most appropriate course of action for anyone considering this combination
Here are the key recommendations: 1 Type 2 Diabetes with No Relevant Comorbidities First-line therapy: Modified-release Metformin + SGLT2 inhibitor If Metformin is contraindicated or not tolerated: SGLT2 inhibitor monotherapy 2 Type 2 Diabetes with Heart Failure Initial therapy: Modified-release Metformin + SGLT2 inhibitor If Metformin cannot be used: SGLT2 inhibitor alone 3 Type 2 Diabetes with Atherosclerotic Cardiovascular Disease (ASCVD) Recommended combination therapy: Metformin SGLT2 inhibitor Semaglutide (up to 1 mg weekly) If Metformin is contraindicated: SGLT2 inhibitor + Semaglutide 4 Early-Onset Type 2 Diabetes Initial treatment: Modified-release Metformin + SGLT2 inhibitor Consider adding: GLP-1 receptor agonist or Tirzepatide for improved glycemic and cardiometabolic outcomes 5 Type 2 Diabetes with Obesity Recommended first-line therapy: Modified-release Metformin + SGLT2 inhibitor Additional weight-focused therapies may be considered based on individual patient needs
Available options may include compounded semaglutide, compounded tirzepatide, or other therapies when appropriate
Weight Management Starts with Better Absorption WLP-1 Oral GLP-1 Support and Berberine work together across four metabolic pathways to reduce cravings, boost satiety, and support healthy blood sugar, with up to 20x more absorption
